Literature DB >> 12874527

[Mucocutaneous bullous pemphigoid induced by valsartan. A clinical case].

F Femiano1.   

Abstract

In the presence of immune-mediated vesiculo-bullous diseases, the oral pathologist should focus his attention not only on the diagnosis and treatment of the case, but should particularly investigate the state of genetic predisposition in relation to the HLA haplotype structure and look for the possible trigger factors for the disease. The detection of the trigger may guarantee a faster cure with a minimum therapeutic contribution. In the search for triggering factors, the drugs that are traditionally incriminated such as ACE inhibitors, Fans, antibiotics (penicillin and penicillamine), substances with -SH groups, tranquillisers, are not always involved in inducing vesiculo-bullous diseases. Substances considered innocuous are often to blame. We present a case of mucous-cutaneous bullous pemphigoid induced by an anti-hypertensive of the sartan group, valsartan.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12874527

Source DB:  PubMed          Journal:  Minerva Stomatol        ISSN: 0026-4970


  4 in total

1.  Lisinopril-associated bullous pemphigoid in an elderly woman: a case report of a rare adverse drug reaction.

Authors:  Rami A Ballout; Umayya Musharrafieh; Joe Khattar
Journal:  Br J Clin Pharmacol       Date:  2018-08-29       Impact factor: 4.335

2.  Angiotensin-II mediates nonmuscle myosin II activation and expression and contributes to human keloid disease progression.

Authors:  Jennifer E Bond; Andrew Bergeron; Peter Thurlow; M Angelica Selim; Edith V Bowers; Anna Kuang; Howard Levinson
Journal:  Mol Med       Date:  2011-07-21       Impact factor: 6.354

3.  Severe acute interstitial nephritis induced by valsartan: A case report.

Authors:  Tong Chen; Peng-Cheng Xu; Shui-Yi Hu; Tie-Kun Yan; Jian-Qing Jiang; Jun-Ya Jia; Li Wei; Wen-Ya Shang
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

4.  Valsartan-associated bullous pemphigoid initially presenting as erythema multiforme.

Authors:  Zhe Gao; Yongping Cao; Xiaofang Zeng; Xiuzu Song
Journal:  Health Sci Rep       Date:  2021-12-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.